Immunotherapy, the promising therapy which harnesses the power of the body’s immune response to target cancer cells, may be advanced by a new minifridge bioreactor developed by researchers at Washington State University. This bioreactor can quickly manufacture T cells, cancer-killing white blood cells, at 95 percent of the maximum growth rate, which is 30 percent faster than other current technologies. The team used T cells from cattle, developed by co-author Bill Davis of WSU’s Veterinary College, and expect it will perform similarly on human cells.
Machine could make CAR T-cell therapy more accessible
